Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | PDCD1LG2 | Q9BQ51 | 4/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.32 |
| ▸ | TUBB | P07437 | 1/20 | 0.32 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.32 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.32 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.32 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.32 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.32 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.32 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.32 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.32 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.32 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13136015 | 0.84 | MBOAT4 (0.46) | MBOAT4PDE4BTRPV1TUBB4ATUBB | |
| SCHEMBL17986246 | 0.83 | MBOAT4 (0.45) | MBOAT4PDE4BTRPV1HSD17B10TUBB4A | |
| SCHEMBL23287266 | 0.83 | MBOAT4 (0.45) | MBOAT4PDE4BTRPV1PDCD1LG2CD274 | |
| SCHEMBL2528780 | 0.83 | MBOAT4 (0.48) | MBOAT4PDE4BTRPV1PDCD1LG2CD274 | |
| SCHEMBL13757105 | 0.83 | MBOAT4 (0.45) | MBOAT4PDE4BTRPV1PDCD1LG2CD274 | |
| SCHEMBL12993561 | 0.80 | MBOAT4 (0.44) | MBOAT4TRPV1HSD17B10 | |
| SCHEMBL27181500 | 0.80 | MBOAT4 (0.46) | MBOAT4PDE4BTRPV1PDCD1LG2CD274 | |
| SCHEMBL2129756 | 0.80 | MBOAT4 (0.49) | MBOAT4PDE4BTRPV1PDCD1LG2CD274 | |
| SCHEMBL3552064 | 0.78 | TRPV1 (0.43) | MBOAT4PDE4BTRPV1HSD17B10TUBB4A | |
| SCHEMBL404270 | 0.77 | KDM4E (0.39) | MBOAT4PDE4BTRPV1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497382-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| CN-119874674-A | GLP-1R modulating compounds | 吉利德科学公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-114630823-B | GLP-1R Modulating Compounds | 吉利德科学公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20230391747-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-12-07 | — | — | US | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2023111181-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-06-22 | — | — | WO | disclosed |
| EP-4048664-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-114630823-A | GLP-1R modulating compounds | 吉利德科学公司 | 2022-06-14 | — | — | CN | disclosed |
| US-20210171499-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2021081207-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-7452892-B2 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452892-B2 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452892-B2 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1891068-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| WO-2006138734-A1 | TRIAZOLOPYRIMIDINE CANNABINOID RECEPTOR 1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006138695-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287341-A1 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287341-A1 | Triazolopyrimidine cannabinoid receptor 1 antagonists | CNR1, CNR2, GPR68 | MBOAT4 3951/4885PDE4B 1693/4885TRPV1 7/4885 |
| US-11702404-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | MBOAT4 317/4885PDE4B 112/4885TRPV1 849/4885 |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | CNR1, CNR2, TRPV1 | MBOAT4 4270/4885PDE4B 1691/4885TRPV1 3/4885 |
| US-20230391747-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | MBOAT4 317/4885PDE4B 112/4885TRPV1 849/4885 |
| US-20210171499-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | MBOAT4 317/4885PDE4B 112/4885TRPV1 849/4885 |
| US-12497382-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | MBOAT4 317/4885PDE4B 112/4885TRPV1 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.